# Terns Pharmaceuticals, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Terns Pharmaceuticals, Inc.). ## Overview Terns Pharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for oncology and metabolic diseases. Its pipeline includes internally discovered drug candidates such as TERN-701 and TERN-501, along with the TERN-800 series of GIPR modulators for obesity. ## Products & services • TERN-701 oncology drug candidate • TERN-501 oncology drug candidate • TERN-800 series GIPR modulators • TERN-801 development candidate • Preclinical and clinical-stage drug development - **Oncology pipeline** (0%) — Small-molecule drug candidates for cancer treatment, including TERN-701 and TERN-501. - **Metabolic disease pipeline** (0%) — Obesity-focused programs built around GIPR modulation and combination approaches. - **Discovery and preclinical development** (0%) — Internal discovery, preclinical research, and candidate nomination activities. - **Clinical development** (0%) — Human clinical testing and related regulatory development for pipeline assets. - **Out-licensing and partnering** (0%) — Potential milestone-based collaboration and license arrangements for select programs. - TERN-701 oncology drug candidate - TERN-501 oncology drug candidate - TERN-800 series GIPR modulators - TERN-801 development candidate - Preclinical and clinical-stage drug development ## Customers Terns does not sell commercial products; its direct counterparties are primarily pharmaceutical partners, contract research organizations, contract manufacturers, and regulators supporting development. If programs advance, the eventual end customers are patients and prescribing physicians in oncology and obesity care, with reimbursement decisions made by payors. - **Strategic pharmaceutical partners** (primary) — Potential licensees or collaborators that may fund or regionalize development of TERN-701 or metabolic assets. - **CRO and CMO vendors** (primary) — Service providers that support discovery, manufacturing, and clinical execution. - **Regulatory agencies** (primary) — FDA and foreign regulators that review INDs, trial plans, and marketing applications. - **Future oncology patients** (emerging) — Patients who would ultimately receive TERN-701 or related oncology therapies if approved. - **Future obesity patients** (emerging) — Patients who would ultimately receive GIPR-based metabolic therapies if approved. - Pharmaceutical partners for licensing and regional development rights - CROs running preclinical studies and clinical trials - CMOs manufacturing drug substance and trial materials - Regulators reviewing INDs and clinical development packages - Future patients and physicians in oncology and obesity ## Geography Terns is headquartered in the United States, but its development footprint is international because clinical trials, suppliers, and potential partners span China, Europe, Canada, and other jurisdictions. The company also references a greater China licensing arrangement for TERN-701, which makes regional partnering an important part of its geographic exposure. - United States headquarters and primary corporate operations - Clinical development and regulatory interactions centered in the U.S. - China exposure through suppliers, trials, and a greater China license - Europe and other countries used for global trial execution - Canada and other international jurisdictions in the supply chain ## Strategy Terns is prioritizing advancement of its oncology lead program, especially TERN-701, while maintaining a selective approach to metabolic assets. The company also seeks strategic partnerships for certain programs, using collaboration to extend development reach and potentially share risk and capital needs. - **Advance TERN-701** (short-term) — The company views this as its most important internal program and a key value driver. - **Partner selected programs** (short-term) — Partnerships can provide external funding, regional reach, and development support. - **Build obesity pipeline selectively** (medium-term) — GIPR modulation may create combination opportunities with GLP-1 therapies. - Advance TERN-701 as the lead internal program - Use partnering to progress selected assets and regions - Continue discovery work on GIPR biology for obesity - Focus resources on programs with the strongest rationale - Preserve optionality through milestone-based licensing ## Risks Terns faces the typical risks of a clinical-stage biotech company: clinical failure, regulatory delay, and dependence on external capital and partners. Its programs also face intense competition in oncology and obesity, while international sourcing and trial activity create exposure to China-related trade and supply-chain disruption. - **Clinical development failure** [high] — Drug candidates may not demonstrate acceptable efficacy, safety, or tolerability. - **Regulatory delay or disruption** [high] — FDA and foreign agency disruptions can slow guidance, review, and approvals. - **China trade and supply-chain exposure** [high] — Manufacturers, suppliers, and trial activity in China can be affected by tariffs, sanctions, or export restrictions. - **Partnering and commercialization risk** [medium] — Potential collaborators may demand favorable economics or decline to partner if competing assets look stronger. - **Funding dependence** [high] — The company has no product revenue and relies on external financing to fund development. - Clinical trials may fail to show sufficient efficacy or safety - FDA or foreign regulatory delays can slow development timelines - Competition in oncology and obesity is intense and well-funded - China-linked suppliers and trials create trade and supply risk - Partnering terms may be difficult to secure on favorable terms ## Accounting As a clinical-stage biotech, Terns’ reported results are driven mainly by research and development expense recognition, which depends on vendor progress and the timing of clinical and manufacturing work. Revenue is currently absent from product sales, so any future milestone or license revenue would be highly judgmental and tied to contract terms and development events. - **Research and development accruals** — Can shift operating loss between periods - **License and milestone revenue** — Could create lumpy revenue recognition - **Stock-based compensation** — Affects G&A expense and equity dilution - **Capitalized prepayments and trial costs** — Affects timing of expense recognition - R&D expense recognition depends on CRO and CMO progress estimates - Clinical and preclinical costs can create quarter-to-quarter volatility - Future license milestones would require contract-based revenue recognition - Cash, marketable securities, and runway assumptions matter for going-concern analysis - Stock-based compensation and equity financing affect reported losses --- *Last updated: 2026-04-29T05:03:23.381193+00:00*